Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

Antibody Drug Conjugates: Chemistry, Biology, Pharmacokinetics and Toxicology


Speakers: Jagath Junutula (Cellerant), Andy Polson (Genentech) , Toni Kline (Sutro), Chetana Rao (BMS), Donglu Zhang (Genentech), Keyang Xu, PhD (Genentech), Melissa Schutten (Genentech)
Organizers: Thomas Pillow (Genentech)
Date: 2018-09-12
Time: 8:45-16:00 Pacific Time
Registration fee: (USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Applied BioMath, LLC; Intertek
Vendor show vendors registered to date: (24)AIT Bioscience; Alturas Analytics; Applied StemCell, Inc.; Averica Discovery Services; BioPharmEquip; Bruker; Bruker; Celerion; JOINN Labs; KCAS Bio; MabPlex; Medpace; MicroConstants; Pacific BioLabs; PHARMout Laboratories; Promega; QPS; SCIEX; Sekisui XenoTech, LLC; Selvita Inc.; Sepax Technologies; Sigma Aldrich; SRI International; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2018-09-11  (it will close sooner if the seating cap is reached)

About the Topic

Linking a small-molecule cytotoxic drug to a monoclonal antibody takes the strengths of both while potentially mitigating the liabilities. The resulting bioconjugates, known as antibody−drug conjugates or ADCs, have been validated clinically, with four approved anti-cancer agents for solid and hematological cancers. This workshop will broadly discuss the strategies for designing, constructing and analyzing ADCs utilizing the latest advances in the field.

This workshop will cover the following specific topics:

  • Overview of antibody-drug conjugates (ADCs) and clinical progress
  • Selecting a target for ADCs
  • The chemistry of linkers and drugs
  • Site-specific conjugation
  • Analytical characterization of ADCs
  • ADC bioanalysis & pharmacokinetics
  • Preclinical safety/toxicology

Workshop Agenda: 

Time Topic  Presenter
8:45-9:00 Welcome and Introduction Thomas Pillow
9:00-9:45 1. ADC Discovery & Development Jagath Junutula
9:45-10:30 2. ADCs for Hematological Malignancies Andy Polson
10:30-10:45 Break  
10:45-11:30 3. Conjugation Modalities for ADC Generation Chetana Rao
11:30-12:30 Lunch  
12:30-1:15 4. ADC Chemistry Toni Kline
1:15-2:00 5. Small Molecule DMPK for ADCs Donglu Zhang
2:00-2:15 Break  
2:15-3:00 6. Bioanalysis of ADCs   Keyang Xu
3:00-3:45 7. ADC Safety/Toxicity Melissa Schutten
3:45-4:15 Panel Discussion All
4:15-4:30 Final Remarks Thomas Pillow

 


2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Online Workshop] Career Transition for Research Scientists
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 3/29/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad